gene-modified T cells targeted

Phase 1Biologic

MMemorial Sloan Kettering Cancer Center

gene-modified T cells targeted is one of 52 biologic programs targeting Leukemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeukemiaActive, not recruiting

LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

119 competitors in Leukemia

#DrugCompanyPhaseTrials

Cytosar

Teva

Phase 3

52 2

Trexall

Jazz Pharmaceuticals

Phase 3

30 3

Fludara

Sanofi

Phase 3

21 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

57 5

Rituxan

Roche

Phase 3

16 6

Adriamycin

Pfizer

Phase 3

11 7

Oncovin

Eli Lilly

Phase 3

10 8

Decadron

AAspen Global Incorporated

Phase 3

24 9

Vepesid

Nexavar

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Leukemia

NCT01044069

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

Biological Therapy in Treating Patients With Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00002637·25 enrolled

Neuroblastoma1 trial

Gene Therapy in Treating Children With Refractory or Recurrent Neuroblastoma

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00002748·38 enrolled

Leukemia1 trial

A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT01044069·93 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for gene-modified T cells targeted. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gene-modified T cells targeted compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gene-modified T cells targeted. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: MMemorial Sloan Kettering Cancer Center

gene-modified T cells targeted

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Prostate Cancer1 trial

Neuroblastoma1 trial

Leukemia1 trial

References

Drug Info

Quick Facts

Related News